AMGN: AMGEN is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. It concentrates on human therapeutics and focuses on medicines based on advances in cellular and molecular biology.
Closing Price: 53.53 on 3/11/11
52-Week Price Range: 51.78-53.87
Risk: You need to further evaluate AMGN thoroughly. Well-informed, you decide what to do. Remember that there is risk of loss in all trading. I don’t own any AMGN shares. Here are the pluses and minuses.
+ Beta: 0.40
+ Debt: 10,874.0 million
– Dividend: AMGN does not presently pay a dividend.
+ Earnings: For the first quarter of 2011, analysts estimate AMGN will earn $1.29 per share and that is an increase of 9.10% from the 2010 first-quarter earnings per share of $1.18.
+ Free Cash Flow: 5.40
+ Morningstar Rating: 4-star
+ PE: 12.30
– Price/Book Ratio: 2.04
– Price/Sales Ratio: 3.25
+ Sales: 15,053.0 million in trailing 12-month sales